Truist cuts Boston Scientific stock price target on Watchman concerns By Investing.com

Truist cut Boston Scientific’s price target to $90 from $92 while keeping a Buy rating, citing softer Watchman momentum and decelerating trends in Watchman and electrophysiology after Q4 2025. The firm expects Q1 2026 results on April 22 to come in within guidance, but sees Watchman growth at 18% year over year versus 22% consensus and potential 2026 organic revenue guidance easing to about 8%+ from 10%–11%.

Analysis

BSX is moving from a multiple-expansion story to a sentiment-reset story: the core issue is not absolute growth, but whether management can preserve the premium by proving the Watchman deceleration is a timing issue rather than a durability issue. When a med-tech leader loses confidence around a flagship franchise, the market usually compresses the entire portfolio multiple first and asks questions later; that creates a window where even good quarterly execution can fail to re-rate the stock until guidance is re-anchored.

The second-order effect is on competitors and category capital allocation. If Watchman growth is perceived as slowing, the debate shifts toward whether procedure share is being delayed, not lost, which would benefit rival structural-heart players over a 1-2 quarter horizon. In electrophysiology, in-line results may not be enough if peers are showing better cadence; the market will likely reward names with clearer elective-procedure visibility and penalize any company with a “good but not great” guide, especially in a tape where investors are paying for acceleration.

The key catalyst path is asymmetric: near-term downside is driven by guidance risk into the print, while upside likely requires either a guide reset that is smaller than feared or evidence that CHAMPION-related adoption offsets CLOSURE-AF drag faster than expected. The stock’s proximity to the low end of its range means the market is already pricing in disappointment, but not yet a full narrative break; that makes the next 4-8 weeks decisive. If management cuts organic growth only modestly and frames it as transitory, the stock can rally sharply on positioning cover; if not, a 10-15% drawdown is plausible as long-only holders de-risk.

Contrarianly, the consensus may be over-anchored to headline Watchman growth and underestimating the valuation support from a high-quality base business with recurring procedure demand. The better way to express that view is not outright size-up stock ownership, but to wait for post-print volatility and buy only if the company can show that the miss is contained to one franchise rather than a broader demand slowdown.

Key Decisions for Investors

• Buy BSX only on post-earnings weakness if management trims 2026 organic growth by <=200 bps and reiterates full-year EPS: target a 10-15% rebound over 4-6 weeks as shorts cover; cut if guide reduction exceeds 300 bps.
• If already long BSX, reduce 25-35% into the print and re-enter after guidance; the risk/reward is skewed to a volatility event, not a steady rerate, over the next 2-4 weeks.
• Pair trade: long a higher-visibility med-tech peer basket vs short BSX into earnings for 30-60 days; this isolates execution-quality premium loss while keeping sector beta more neutral.
• For event-driven accounts, buy BSX straddles/strangles into the April 22 print if implied move is below the expected guidance reset range; downside is defined, and a larger-than-expected cut could pay quickly over 1-5 trading days.
• If CHAMPION follow-through data becomes available within 1-3 months and confirms adoption offset, add BSX on confirmation rather than anticipation; the highest upside comes from a second-leg rerating, not the first relief bounce.